Anticholinesterases For The Anaesthetically Adept
Anticholinesterases for FRCA: mechanism of action, neostigmine pharmacology, muscarinic side effects, organophosphate poisoning, and acetylcholine synthesis at the NMJ.
19 Apr 2026
57 episodes
Anticholinesterases for FRCA: mechanism of action, neostigmine pharmacology, muscarinic side effects, organophosphate poisoning, and acetylcholine synthesis at the NMJ.
19 Apr 2026
Sugammadex pharmacology for FRCA: mechanism, dosing by block depth, pharmacokinetics, anaphylaxis incidence, and the contraceptive interaction.
1 Apr 2026
Pancuronium bromide: aminosteroid pharmacology, vagolytic cardiovascular effects, and Phase I vs Phase II neuromuscular blockade for FRCA preparation.
22 Mar 2026
Vecuronium: aminosteroid non-depolarising neuromuscular blocker. Pharmacology, dosing, kinetics, cardiovascular profile, and monitoring for FRCA candidates.
26 Feb 2026
Cisatracurium is the 1R-cis, 1'R-cis isomer of atracurium — three times as potent, 'histamineless', and eliminated by Hofmann degradation regardless of organ function.
18 Feb 2026
Mivacurium: plasma cholinesterase-metabolised NMB. FRCA: isomers, context-insensitive offset, histamine release, and cholinesterase deficiency.
1 Feb 2026
Oxygen pharmacology for FRCA Primary: fractional distillation, cylinder pressures, oxygen toxicity, COPD hypercapnia, and BTS dosing targets.
22 Jan 2026
Nitrous oxide pharmacology: MAC of 105%, NMDA receptor antagonism, diffusion hypoxia, vitamin B12 oxidation, Entonox, and the concentration effect.
9 Jan 2026
Di-ethyl ether and enflurane: GABA-A volatile anaesthetic agents with high blood:gas partition coefficients, MAC values, side-effect profiles, and a guide to theatre fires, deflagration, and detonation for the FRCA.
29 Dec 2025
Desflurane pharmacology for the FRCA: MAC, SVP, boiling point, Tec 6 vaporiser anatomy, temperature compensation, altitude effects, and why the NHS decommissioned it.
11 Dec 2025
Halothane: physico-chemical properties, MAC, cardiovascular effects, and the two types of halothane hepatitis with mechanisms + (and fewer explosions).
27 Nov 2025
Hypnotic drugs for the FRCA Primary: propofol, ketamine, thiopentone, etomidate, midazolam, clonidine, and dexmedetomidine — pharmacology, mechanisms, and clinical use.
17 Nov 2025
Sevoflurane pharmacology for the FRCA Primary — physico-chemical properties, MAC (2.0%), pharmacodynamics, gas induction advantages, and Compound A degradation.
12 Nov 2025
Isoflurane pharmacology for the FRCA Primary: physico-chemical properties, MAC, blood:gas solubility, pharmacodynamics, pharmacokinetics, and Dalton's Law.
29 Oct 2025
Volatile anaesthetic agents — SVP, blood-gas and oil-gas partition coefficients, MAC, and wash-in curves — explained for FRCA Primary candidates.
17 Oct 2025
Clonidine is a partial alpha-2 adrenoceptor agonist. Covers mechanism, biphasic cardiovascular effects, kinetics, and ITU sedation — essential FRCA Primary pharmacology.
3 Oct 2025
Dexmedetomidine (Dexdor) is a highly selective α2-adrenoceptor agonist producing cooperative sedation without respiratory depression — FRCA pharmacology with dosing and clinical applications.
26 Sept 2025
Midazolam for FRCA Primary: GABA-A positive allosteric modulator, 96% protein-bound, CYP3A4 hepatic metabolism. Anterograde amnesia, MAC-sparing, dosing by route, flumazenil reversal.
17 Sept 2025
Etomidate inhibits 11β-hydroxylase, causing adrenal suppression for 24–48 hours after a single dose. FRCA pharmacology: mechanism, kinetics, and cardiovascular stability.
12 Sept 2025
Stereochemistry and isomer classification for the FRCA Primary: structural, geometric, and optical isomers — levobupivacaine and S-ketamine explained.
5 Sept 2025
Complete FRCA Primary guide to local anaesthetics: sodium channel pharmacology, amide vs ester classification, individual drug profiles, LAST management, and perineural adjuncts.
30 Aug 2025
Perineural adjuncts prolong regional blocks but are off-license. Covers dexamethasone, clonidine, and dexmedetomidine, — mechanisms, efficacy, and FRCA viva.
29 Aug 2025
Pharmacological comparison of amide and ester local anaesthetics — onset, duration, cardiotoxicity, and maximum doses — for FRCA Primary candidates.
25 Aug 2025
Local anaesthetic pharmacology quiz for FRCA Primary: mechanism, amide vs ester classification, pKa, protein binding, max doses, toxicity, and Intralipid rescue.
25 Aug 2025
LAST pharmacology, recognition, and intralipid management for the FRCA Primary — mechanism, dosing protocol, and three viva-ready question frameworks.
14 Aug 2025
Ropivacaine pharmacology for FRCA Primary: S-enantiomer structure, differential motor blockade, cardiotoxicity comparison with bupivacaine, and max dose.
7 Aug 2025
Complete opioid pharmacology series for the FRCA Primary: receptor mechanisms, PK/PD profiles, neuraxial kinetics, and viva decision-making for all major opioids.
4 Aug 2025
Lidocaine: amide local anaesthetic, class 1b antiarrhythmic, IV infusion agent. Mechanism, dosing, TNS risk, and LAST management for the FRCA Primary.
30 Jul 2025
Prilocaine pharmacology for FRCA Primary: mechanism of sodium channel blockade, methaemoglobinaemia risk, spinal dosing, EMLA composition, and TNS data.
23 Jul 2025
Cocaine pharmacology for the FRCA Primary: ester local anaesthetic, sympathomimetic mechanism, ENT clinical use, cocaethylene, and toxicity management.
17 Jul 2025
Bupivacaine pharmacology for the FRCA Primary: sodium channel blockade, cardiotoxicity, CC:CNS ratio, dosing, additives, and levobupivacaine — the safer S-enantiomer.
8 Jul 2025
Local anaesthetics block voltage-gated sodium channels. This episode covers pKa, nerve fibre classification, ester–amide pharmacology, and LAST management.
25 Jun 2025
Comparing opioids for the FRCA Primary: pharmacokinetics, context-sensitive half-time, neuraxial selection, renal failure prescribing, and receptor pharmacology.
17 Jun 2025
Remifentanil pharmacology for the FRCA: ester hydrolysis, context-sensitive half-time, opioid-induced hyperalgesia, and the Minto TCI model effect-site targets.
9 Jun 2025
Neuraxial opioid pharmacology for FRCA: lipid solubility, pKa, and molecular weight govern epidural and intrathecal behaviour of morphine, fentanyl, and diamorphine.
1 Jun 2025
Diamorphine pharmacology for the FRCA Primary: mechanism of action at mu opioid receptors, pro-drug metabolism to 6-O-acetylmorphine, neuraxial use, and M6G accumulation in renal failure.
29 May 2025
Oxycodone: semi-synthetic opioid, 60–87 % oral bioavailability, CYP3A4/2D6 metabolism, and equipotency conversions for FRCA Primary pharmacology.
22 May 2025
Methadone pharmacology for FRCA Primary: µ-opioid agonist, NMDA antagonist, CYP3A4/2D6 metabolism, QT prolongation, and opioid substitution therapy.
10 May 2025
Tramadol pharmacology for the FRCA Primary: multimodal mechanism (mu-opioid, noradrenaline, serotonin), CYP2D6 metabolism, active metabolite, serotonin syndrome.
7 May 2025
Alfentanil is a short-acting μ-opioid receptor agonist used in RSI, ICU sedation, and acute analgesia — FRCA Primary pharmacology examined in full.
28 Apr 2025
Multi-compartmental pharmacokinetic models, context-sensitive half time, and the effect site explained for FRCA Primary candidates.
20 Jan 2025
Pharmacokinetic compartment models for FRCA: half-life, time constant, bi-exponential decay, and Fick's Law — the foundation of TCI dosing.
8 Jan 2025
Suxamethonium: depolarising neuromuscular blocker, 30 s onset. FRCA pharmacology — mechanism, side effects, sux apnoea, malignant hyperthermia.
29 Nov 2024
Morphine for the FRCA Primary: mu-opioid receptor mechanism, pharmacokinetics, M3G/M6G metabolites, and intrathecal delayed respiratory depression.
22 Nov 2024
Ketamine pharmacology for the FRCA Primary: NMDA receptor antagonism, dissociative anaesthesia, dosing, pharmacokinetics, and cardiovascular effects.
17 Nov 2024
Compare sevoflurane, isoflurane and desflurane for the FRCA: MAC values, blood:gas and oil:gas partition coefficients, SVP, boiling points, and global warming potential.
11 Nov 2024
Atracurium: benzylisoquinolinium NMB with Hofmann elimination. Organ-independent clearance, dosing, side effects, and laudanosine — FRCA Primary pharmacology.
9 Nov 2024
Minimum alveolar concentration (MAC), blood:gas and oil:gas partition coefficients, wash-in curves, and MAC variants explained for FRCA Primary candidates.
9 Nov 2024
Michaelis-Menten kinetics explain enzyme saturation, Km, Vmax, and the transition between first-order and zero-order kinetics — core FRCA Primary pharmacology.
9 Nov 2024
Thiopentone pharmacology for FRCA Primary: GABA-A mechanism, tautomerism, zero-order kinetics, cardiovascular and CNS effects, contraindications, and RSI use.
9 Nov 2024
Sevoflurane pharmacokinetics for FRCA: wash-in, wash-out, compartmental distribution, blood-gas partition coefficient, MAC factors, and low-flow technique.
8 Nov 2024
Fentanyl pharmacology for FRCA Primary: mu-opioid receptor mechanism, pharmacokinetics, opioid receptor subtypes (MOP/DOP/KOP/NOP), and clinical dosing.
8 Nov 2024
Hepatic clearance, extraction ratio, and intrinsic clearance explained for the FRCA Primary — how hepatic blood flow and protein binding govern drug elimination.
8 Nov 2024
Propofol pharmacology for FRCA: GABA-A mechanism, three-compartment kinetics, propofol infusion syndrome (PRIS), and TIVA dosing.
8 Nov 2024
Rocuronium pharmacology for FRCA Primary: mechanism of action, dosing, pharmacokinetics, sugammadex reversal, and neuromuscular junction.
8 Nov 2024
Volume of distribution (Vd) is a core FRCA pharmacokinetic concept — a theoretical apparent volume explaining why drugs distribute differently across patients and tissues.
8 Nov 2024
pKa is the pH at which a drug is 50% ionised and 50% unionised. Governing onset speed, membrane crossing, and local anaesthetic behaviour. Essential for the FRCA Primary.
8 Nov 2024